Pembrolizumab in the treatment of non-small cell lung cancer—experiences from clinical practice
Our findings confirm the clinical benefit of pembrolizumab in a real-world setting, despite lower ORR compared to clinical trial data. However, the prognosis remains guarded due to the advanced stage and comorbidities of the population. Further investigation is warranted to optimize patient selection and treatment strategies.
Authors
- Marko Novakovic
- Mirko Turic
- Lora Novaković Lacković (ORCID: https://orcid.org/0000-0002-7588-1477)
- Мirko Stanetić
- Marija Tomić
- Aleksandra Kajkut
- Teodora Macinkovic
- Ranko Glamocak
Institutions
- University of Banja Luka (BA)
- University clinical center of Republika Srpska (BA)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.3389/fmed.2025.1635626
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00